PI3 and prostate carcinoma: Since PI3-AKT signaling has been shown to have pro-survival and pro-proliferative roles in prostate cancer [30], something we confirmed by using the PI3 inhibitor LY294002 [30], we hypothesized that Peptide A-8R will interfere with the sGCα1 positive effect on AKT.